| 2.28 -0.05 (-2.15%) | 12-05 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.01 | 1-year : | 3.51 |
| Resists | First : | 2.57 | Second : | 3.01 |
| Pivot price | 2.15 |
|||
| Supports | First : | 2.22 | Second : | 2 |
| MAs | MA(5) : | 2.2 |
MA(20) : | 2.19  |
| MA(100) : | 2.32 |
MA(250) : | 2.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 58.8 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 5.03 | Low : | 1.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACST ] has closed below upper band by 0.6%. Bollinger Bands are 49.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.34 - 2.36 | 2.36 - 2.37 |
| Low: | 2.12 - 2.14 | 2.14 - 2.15 |
| Close: | 2.31 - 2.33 | 2.33 - 2.36 |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Tue, 14 Nov 2023
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely? - Simply Wall St
Mon, 13 Nov 2023
Acasti: Fiscal Q2 Earnings Snapshot - Quartz
Mon, 13 Nov 2023
Acasti: Fiscal Q2 Earnings Snapshot - Houston Chronicle
Tue, 26 Sep 2023
Acasti Announces $7.5 Million Private Placement Equity Financing - Yahoo Finance
Tue, 26 Sep 2023
Why Acasti Pharma (ACST) Stock Is Exploding Higher - Acasti Pharma (NASDAQ:ACST) - Benzinga
Wed, 09 Aug 2023
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 92 (K) |
| Shares Short P.Month | 112 (K) |
| EPS | -5.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -48.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|